There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Appili Therapeutics
Tag: APLIF
Maxim Group Sticks to Their Buy Rating for Appili Therapeutics Inc Class A (APLIF)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Appili Therapeutics Inc Class A